Project Grant R43AG097214
Award Date 9/25/25
Completion Date 9/24/26
Dollars Obligated $306K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Bethesda, MD 20852, USA
Similar Awards
- Federal Project Grant Award Summary Redwood Neuro Inc. received a $506,061 Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) awarded on September 15, 2025, with a completion date of August 31, 2026. The awardee will develop and validate the SimoLISA platform, an ultra-sensitive, cost-effective immunoassay technology designed to democratize early detection and longitudinal monitoring of Alzheimer's disease (AD). The platform employs a proprietary...
- Federal Grant Award Summary Award Details: The National Institute on Aging (Aging Research program, CFDA 93.866) awarded Adeptrix Corp a Project Grant of $499,940 on September 11, 2025, with an ultimate completion date of August 31, 2026. The award supports research and development conducted in Massachusetts. Products and Services: Adeptrix is developing TAUTRACE, an ultrasensitive immunoassay platform designed to detect and quantify phosphorylated tau (pTau) biomarkers in cerebrospinal fluid...
- Federal Project Grant Summary Award Details: Novoron Bioscience Inc. received a $3.76 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded on September 16, 2025, with a completion date of May 31, 2027. Products and Services: The grant funds development of a platform technology using human induced pluripotent stem cell (hiPSC)-derived neural spheroids to screen and identify compounds that block tau propagation in Alzheimer's...
- Federal Project Grant Award Summary Meganano Diagnostics Inc. received a $483,346 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded on September 15, 2025, with a completion date of August 31, 2026. The grant funds the development of an reverse transcription quantitative polymerase chain reaction (RT-qPCR) assay designed to enable early diagnosis of Alzheimer's disease (AD) using accessible peripheral blood biomarkers. The project...
- Federal Project Grant Award Summary Cellsight Technologies, Inc. received a $871,261 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded on September 20, 2025, with a completion date of August 19, 2028. The company will conduct research to characterize and validate [18F]F-ARAG, a positron emission tomography (PET) imaging agent, as a biomarker for detecting and quantifying T cell immunity in patients with Alzheimer's disease. The primary...
- Federal Grant Award Summary Artiam Bio Inc., a minority-owned small disadvantaged biotechnology company, received a $571,792 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded September 20, 2025, with completion targeted for May 31, 2027. The award funds research to validate APT101, a selective apelin receptor (APJ) agonist, as a therapeutic intervention for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in an aging...
- Federal Project Grant Award Summary Ceiba Bio Inc. received a $506,198 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) to develop platelet-derived exercise mimetics as a therapeutic treatment for Alzheimer's disease and related dementias. The award was obligated on September 15, 2025, with an ultimate completion date of August 31, 2026. This fast-track Phase I to Phase II proposal aims to translate prior research identifying...
- Federal Project Grant Award Summary T-Neuro Inc. received a $500,000 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) for the period August 1, 2025, through July 31, 2026. The award supports research to confirm and validate the use of aberrant T cells as an amyloid-independent blood biomarker for Alzheimer's disease (AD) diagnosis and disease progression tracking. The research builds on preclinical findings demonstrating that age-related,...
- Summary of Federal Project Grant Award Janusq LLC received a $1.153 million Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded September 22, 2025, with completion targeted for March 31, 2027. The award supports research and development activities focused on evaluating the pharmacokinetics and in vivo efficacy of DA45, a macrocyclic peptide therapeutic candidate, in murine models of Alzheimer's disease. Janusq, a startup biotechnology...
- Federal Project Grant Summary Translucence Biosystems, Inc. received a $2.43 million Project Grant from the National Institute of Mental Health under the Aging Research program (CFDA 93.866), awarded on September 20, 2025, with completion targeted for May 31, 2027. The company is developing and refining a specialized Vasculature Subtraction Parenchymal Quantification (VSPQ) workflow integrated into its proprietary 3D brain imaging and analysis platform. This tool addresses a critical gap in...